Newsfeeds - Spark Newswire

1 minute read

Ipsen To Acquire Albireo For $42.00/Share Plus A Contingent Value Right Of $10.00/Share

Today, 5:45 AM

Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators to treat pediatric and adult cholestatic liver diseases.

ALBO

2 minute read

Have A Look At William Blair’s Top Biotech Picks For 2023

By Vandana Singh

Today, 5:45 AM

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

ALBO

1 minute read

FDA
News

Albireo Submits Bylvay Alagille Syndrome Regulatory Filings To FDA, EMA

By Benzinga Newsdesk

Today, 5:45 AM

- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related

ALBO

8 minute read

Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday

By Lisa Levin

Today, 5:45 AM

Gainers

$APE

6 minute read

Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 5:45 AM

Gainers

ABST

21 minute read

Earnings

Earnings Scheduled For November 8, 2022

By Benzinga Insights

Today, 5:45 AM

Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.

ABCL

1 minute read

HC Wainwright & Co. Maintains Buy on Albireo Pharma, Raises Price Target to $68

By Benzinga Newsdesk

Today, 5:45 AM

HC Wainwright & Co. analyst Ed Arce maintains Albireo Pharma (NASDAQ:ALBO) with a Buy and raises the price target from $54 to $68.

ALBO

2 minute read

Analyst Ratings

What 5 Analyst Ratings Have To Say About Albireo Pharma

By Benzinga Insights

Today, 5:45 AM

Analysts have provided the following ratings for Albireo Pharma (NASDAQ:ALBO) within the last quarter:

ALBO

1 minute read

W. R. Berkley To Rally 25%? Here Are 5 Other Price Target Changes For Wednesday

By Lisa Levin

Today, 5:45 AM

Wells Fargo raised W. R. Berkley Corporation (NYSE: WRB) price target from $83 to $85. Wells Fargo analyst Elyse Greenspan maintained an Overweight rating on the stock. W. R. Berkley shares rose 0.7% to close at $68.06 on Tuesday.

ALBO

1 minute read

Baird Maintains Outperform on Albireo Pharma, Raises Price Target to $55

By Benzinga Newsdesk

Today, 5:45 AM

Baird analyst Brian Skorney maintains Albireo Pharma (NASDAQ:ALBO) with a Outperform and raises the price target from $43 to $55.

ALBO